Hao Zhimin, Jiang Zhencong, Li Jiexiong, Luo Tao
Department of Anesthesiology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Shantou University Medical College, Shantou, China.
BMC Anesthesiol. 2025 Feb 13;25(1):70. doi: 10.1186/s12871-024-02844-8.
Laryngoscopy and endotracheal intubation are known to increase activity of the sympathetic nervous system, and are usually associated with perioperative hypertension, cardiac arrhythmia, and tachycardia. The aim of this study was to determine the effect-site concentrations of remifentanil to inhibit the tracheal intubation response during etomidate anesthesia in elderly patients.
American Society of Anesthesiologists physical status I-III patients aged 65 or older and scheduled for general anesthesia for elective surgery were enrolled in the study. Anesthesia induction was applied with etomidate 0.3 mg/kg, rocuronium 0.6 mg/kg, and target controlled infusion of remifentanil under the Minto pharmacokinetic model. Invasive continuous arterial blood pressure monitoring was used throughout the operation. A positive response was defined if the maximal mean arterial pressure (MAP) or heart rate (HR) within 3 min after tracheal intubation was 20% higher than the baseline value. The Dixon sequential method was used for the test, and the initial effect-site concentrations of remifentanil was 6 ng/ml. The EC and EC for the suppression of endotracheal intubation response by remifentanil were calculated by the probit method.
The EC for inhibiting tracheal intubation response by remifentanil in elderly patients was 6.53 ng/ml (95% CI:6.01-7.05 ng/ml) and EC was 8.05 ng/ml (95% CI:7.32-8.78 ng/ml) when combined with etomidate anesthesia. The changes of MAP, HR and BIS in positive group were significantly higher than those of negative group (P < 0.05). There were no episodes of hypoxemia, muscular tremor, chest wall rigidity or choking cough in both groups.
Target controlled infusion of remifentanil in combination with etomidate is effective preventing hemodynamic instability in elderly patients during the anesthesia induction and endotracheal intubation.
This article was registered at Chinese Clinical Trial Registry ( www.chictr.org.cn registration number: ChiCTR2300076261, date of registration: 28/09/2023).
已知喉镜检查和气管插管会增加交感神经系统的活性,并且通常与围手术期高血压、心律失常和心动过速有关。本研究的目的是确定瑞芬太尼的效应室浓度,以抑制老年患者依托咪酯麻醉期间的气管插管反应。
纳入年龄65岁及以上、美国麻醉医师协会身体状况分级为I-III级、计划接受择期手术全身麻醉的患者。采用0.3mg/kg依托咪酯、0.6mg/kg罗库溴铵进行麻醉诱导,并根据Minto药代动力学模型进行瑞芬太尼靶控输注。术中全程采用有创连续动脉血压监测。若气管插管后3分钟内的最大平均动脉压(MAP)或心率(HR)比基线值高20%,则定义为阳性反应。试验采用Dixon序贯法,瑞芬太尼的初始效应室浓度为6ng/ml。采用概率单位法计算瑞芬太尼抑制气管插管反应的半数有效浓度(EC)和95%可信区间(EC)。
老年患者瑞芬太尼抑制气管插管反应的EC为6.53ng/ml(95%CI:6.01-7.05ng/ml),与依托咪酯麻醉联合应用时EC为8.05ng/ml(95%CI:7.32-8.78ng/ml)。阳性组的MAP、HR和脑电双频指数(BIS)变化显著高于阴性组(P<0.05)。两组均未出现低氧血症、肌肉震颤、胸壁强直或呛咳等情况。
瑞芬太尼靶控输注联合依托咪酯可有效预防老年患者麻醉诱导和气管插管期间的血流动力学不稳定。
本文在中国临床试验注册中心(www.chictr.org.cn,注册号:ChiCTR2300076261,注册日期:2023年9月28日)注册。